Rhabdomyolysis Secondary to a Drug Interaction between Simvastatin and Clarithromycin

Author:

Lee Audrey J1,Maddix Daniel S2

Affiliation:

1. Audrey J Lee PharmD BCPS, Associate Professor of Pharmacy Practice, University of the Pacific, Stockton, CA; Clinical Pharmacist, Internal Medicine, Veterans Affairs Medical Center, San Francisco, CA

2. Daniel S Maddix PharmD, Infectious Diseases Clinical Pharmacist, Pharmacy Service, San Francisco Veterans Affairs Medical Center; Adjunct Faculty, University of the Pacific; Assistant Clinical Professor of Pharmacy, University of California at San Francisco, San Francisco

Abstract

OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin. CASE SUMMARY: A 64-year-old African-American man was admitted to the hospital for worsening renal failure, elevated creatine phosphokinase, diffuse muscle pain, and severe muscle weakness. About three weeks prior to admission, the patient was started on clarithromycin for sinusitis. The patient had been receiving simvastatin for approximately six months. He was treated aggressively with intravenous hydration, sodium bicarbonate, and hemodialysis. A muscle biopsy revealed necrotizing myopathy secondary to a toxin. The patient continued to receive intermittent hemodialysis until his death from infectious complications that occurred three months after admission. There were several factors that could have increased his risk for developing rhabdomyolysis, including chronic renal failure. DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. Other factors may increase the risk of this drug interaction, including the administration of other medications that are associated with myopathy, underlying renal insufficiency, and administration of high doses of HMG-CoA reductase inhibitors. CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). This interaction may result in myopathy and rhabdomyolysis, particularly in patients with renal insufficiency or those who are concurrently taking medications associated with myopathy.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Cited by 97 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Statins, allies against antibiotic resistance?;Current Medicinal Chemistry;2023-08-29

2. Antibiotics case studies: Community pharmacies and primary care and public;Clinical Case Studies on Medication Safety;2023

3. Drug interactions case studies;Clinical Case Studies on Medication Safety;2023

4. A systematic review of the drug–drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2022-02-25

5. Drug-drug interactions with OTC medicines;Therapeutic Drug Monitoring;2021-08-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3